Introduction {#s1}
============

Colorectal carcinoma (CRC) is an important contributor to cancer mortality and morbidity. The lifetime risk of developing CRC in the US is 4--5%, and approximately one-third of CRC patients die from the disease ([@bib46]). Although the pathogenetic mechanisms underlying CRC development are complex and heterogeneous, several critical genes and pathways important in its initiation and progression are well characterized, such as Wnt-APC, Ras-MAPK, p53 and DNA repair pathways ([@bib14]). In addition to these components, mammalian target of rapamycin complex 1 (mTORC1), a protein kinase that is essential for cell growth ([@bib23]; [@bib60]), was recently found to play a key tumorigenic role during CRC development induced by either colitis ([@bib50]) or a genetic mutation ([@bib13]; [@bib22]).

In addition to promoting cancer cell growth, mTORC1 hyperactivation can lead to unrestricted protein synthesis, resulting in the accumulation of unfolded protein, endoplasmic reticulum (ER) stress and tissue injury ([@bib34]; [@bib36]; [@bib58]), which together can contribute to tumor progression ([@bib53]). ER stress has been shown to be critically involved in the pathogenesis of colitis and colon inflammation ([@bib4]; [@bib10]; [@bib26]), which is an important risk factor of CRC development ([@bib51]) and a well-characterized tumor promoter ([@bib21]; [@bib49]). Mechanisms of how the mTORC1 and ER stress signaling pathways are regulated in the colon, especially during colon injury, inflammation and tumorigenesis, are poorly understood.

Sestrins are a family of stress-inducible proteins that are widely conserved throughout animal species ([@bib29]). Sestrins were originally identified as a target of the tumor suppressor p53 ([@bib8]; [@bib52]). Sestrins have two important functions, suppressing reactive oxygen species (ROS) ([@bib7]) and inhibiting mTORC1 ([@bib6]). The ROS-suppressing effect of Sestrins is dependent, at least partially, on mTORC1 inhibition, which promotes autophagic degradation of dysfunctional mitochondria or an Nrf2 inhibitor Keap1 ([@bib3]; [@bib30]; [@bib55]). However, Sestrin can also function as an active oxidoreductase that can directly detoxify ROS such as alkylhydroperoxides ([@bib27]). Sestrins inhibit mTORC1 through the activation of AMP-activated protein kinase (AMPK) and the subsequent inactivation of Rheb GTPases ([@bib6]; [@bib45]). Independently of AMPK, Sestrins can also inhibit Rag GTPases ([@bib11]; [@bib28]; [@bib37]; [@bib38]), which are essential for mTORC1 activity. Sestrin-mediated inhibition of mTORC1 is also critical for limiting protein synthesis upon unfolded protein accumulation ([@bib5]; [@bib36]) or amino acid starvation ([@bib38]; [@bib54]; [@bib57]), thereby suppressing ER stress or nutrient crisis.

In light of these important cellular functions, the present study assessed if Sestrin functions as a coordinator of mTORC1 and ER stress signaling pathways in the colon during intestinal inflammation and carcinogenesis. Our data collected from patient samples, mouse models of colitis and colitis-associated cancer, cultured colon cancer cell lines as well as data mining of large-scale transcriptome analyses, concertedly indicate that Sestrin2, a member of the Sestrin family, is important for proper regulation of mTORC1 and ER stress pathways during colon injury, and thereby functions as a suppressor of colitis and colon cancer development.

Results {#s2}
=======

Loss of Sestrin2 sensitizes mice to colon injury {#s2-1}
------------------------------------------------

Increased ER stress and excessive ROS accumulation are hallmarks of colon inflammation and colitis ([@bib18]; [@bib59]). Sestrins can be induced upon either of these stresses and are critical to dampen their detrimental consequences ([@bib5]; [@bib29]; [@bib36]). Therefore, to understand the role of Sestrins in colitis, expression of Sestrins was analyzed in tissues isolated from patients with ulcerative colitis (UC). Sestrin1 mRNA (*SESN1*) was unaltered in UC ([Figure 1A](#fig1){ref-type="fig"}); however, expression of *SESN2* ([Figure 1B](#fig1){ref-type="fig"}) and *SESN3* ([Figure 1C](#fig1){ref-type="fig"}) was significantly increased in the intestine of patients with UC.10.7554/eLife.12204.003Figure 1.Protective function of Sestrin2 against colon injury.(**A-C**) Upregulation of human *SESN2* and *SESN3* expression in ulcerative colitis (UC). mRNA expression of human *SESN1-3* was analyzed through quantitative RT-PCR of non-inflamed (Normal) and inflamed (UC) colon tissues from patients with UC (n=10; mean ± s.e.m.). These samples were histologically confirmed and formerly described ([@bib56]). (**D-M**) Loss of Sestrin2 impairs recovery from DSS-induced colitis in mice. 6-month-old WT and *Sesn2^-/-^* mice (n=4 each) were treated with 3% DSS in drinking water for 6 days (arrows), followed by 6 days of regular water. Body weight was measured over 12 days (**D**; mean ± s.e.m.). At the final day of the experiment, mice were sacrificed and colon length was measured (**E**). The data are shown as the mean ± s.e.m. The colons were isolated and fixed for H&E staining (**F**), TUNEL staining (**G**), PCNA staining (**H**) and F4/80 staining (**I**). The levels of the indicated mRNAs, which are indicative of active inflammation, were quantified by real-time PCR (**J-M**; mean ± s.e.m.). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. *P* values are from Student's t-test. Scale bars, 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.003](10.7554/eLife.12204.003)10.7554/eLife.12204.004Figure 1---figure supplement 1.Hypersensitivity of *Sesn2^-/-^/Sesn3^-/-^* mice against DSS-induced colon injury.1-year-old WT and *Sesn2^-/-^/Sesn3^-/-^* mice (n=4 each) were treated with 3% DSS in drinking water for 7 days (arrows in **A**), followed by 5 days of regular water.Body weight was measured over 12 days (**A**). At the final day of the experiment, mice were sacrificed and colon length was measured (**B**). The colons were isolated and fixed for H&E staining (**C**), TUNEL staining (**D**), PCNA staining (**E**) and F4/80 staining (**F**). Data are shown as the mean ± s.e.m. \*\**p*\<0.01. *P* values are from Student's t-test. Scale bars, 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.004](10.7554/eLife.12204.004)10.7554/eLife.12204.005Figure 1---figure supplement 2.Acute colon injury is comparable between WT and *Sesn2^-/-^* mice during DSS treatment.2-month-old WT and *Sesn2^-/-^* mice (n=4 each) were treated with 3% DSS in drinking water for 7 days (DSS -- 7d only).At this time point, mice were sacrificed and colon length was measured (**A**). The data are shown as the mean ± s.e.m. The colons were isolated and fixed for H&E staining (**B**). The levels of *Tnfa* and *Xbp1s* mRNAs, which are respectively indicative of active inflammation and ER stress, were quantified by real-time PCR (**C**,**D**; mean ± s.e.m.). Scale bars, 200 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.005](10.7554/eLife.12204.005)

To examine whether colitis-induced Sestrin2 and Sestrin3 play a physiological role in maintaining intestinal homeostasis, WT and *Sesn2^-/-^/Sesn3^-/-^* mice were treated with dextran sulfate sodium (DSS) in the drinking water to induce colitis. DSS treatment for 7 days led to substantial weight loss in both WT and *Sesn2^-/-^/Sesn3^-/-^* mice ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). After placing back on regular water, WT mice recovered their body weight ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). However, *Sesn2^-/-^/Sesn3^-/-^* mice did not show any recovery and continued to lose body weight until the experimental endpoint (5 days during the recovery phase; [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). *Sesn2^-/-^/Sesn3^-/-^* mice also showed a dramatic decrease in colon length when compared to WT mice ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), indicative of strongly exacerbated DSS-induced colitis. Histological examination of colon tissue sections also revealed significant epithelial degeneration in *Sesn2^-/-^/Sesn3^-/-^* mice following the 5 days of recovery from the 7-day DSS treatment, while WT mice exhibited substantial regeneration of epithelial structure at the same time point ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). The increased susceptibility of *Sesn2^-/-^/Sesn3^-/-^* mice to DSS-induced injury ([Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}) was recapitulated in *Sesn2^-/-^* mice; although both WT and *Sesn2^-/-^* mice develop severe colitis with one week of DSS treatment ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), WT mice successfully recovered from injury after one additional week of regular water treatment, while *Sesn2^-/-^* mice did not ([Figure 1D--F](#fig1){ref-type="fig"}). These results demonstrate a critical role for Sestrin2 in restoring intestinal homeostasis after injury.

Sestrin2-deficient mice fail to recover from DSS-induced colitis {#s2-2}
----------------------------------------------------------------

We examined molecular markers for cell death and inflammation in the colons of WT, *Sesn2^-/-^* and *Sesn2^-/-^/Sesn3^-/-^* mice after DSS treatment. At 5 days after DSS injury, WT mice displayed a very small number of apoptotic cells ([Figure 1G](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), consistent with the histological observation showing that the colon epithelium had been restored ([Figure 1F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). However, a significant number of apoptotic cells were observed in the colon epithelium of both *Sesn2^-/-^* and *Sesn2^-/-^/Sesn3^-/-^* mice ([Figure 1G](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), consistent with the degenerative phenotypes observed in these mice. Proliferating cell nuclear antigen (PCNA) staining of WT colon displayed a normal pattern of cell proliferation; PCNA staining is confined to the base of colon crypts in WT mice ([Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}), where epithelial progenitor cells are undergoing homeostatic proliferation that maintains normal turnover of the epithelium. However, the colon epithelium of both *Sesn2^-/-^* and *Sesn2^-/-^/Sesn3^-/-^* mice exhibited an increased number of PCNA-positive cells throughout the degenerated epithelium ([Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). This result suggests that, in order to compensate for the apoptotic loss of epithelial cells, colonocytes of both *Sesn2^-/-^* and *Sesn2^-/-^/Sesn3^-/-^* mice were undergoing active proliferation. Immunohistochemical staining of macrophage marker F4/80 ([Figure 1I](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}), as well as quantitative RT-PCR examination of inflammation markers *Tnfa* ([Figure 1J](#fig1){ref-type="fig"}), *Il6* ([Figure 1K](#fig1){ref-type="fig"}), *Il1b* ([Figure 1L](#fig1){ref-type="fig"}) and *Il10* ([Figure 1M](#fig1){ref-type="fig"}), show that *Sesn2^-/-^* mice had increased the levels of colon inflammation after DSS injury. These data collectively indicate that Sestrin2 deficiency exacerbates DSS-induced colon damage and inflammation.

Sestrin2 expression in the extra-hematopoietic compartment suppresses colitis {#s2-3}
-----------------------------------------------------------------------------

Inflammatory cytokine signaling instigated by bone marrow-derived immune cells, such as macrophages, is known to be important for the progression of colitis as well as colon cancer ([@bib49]). We examined whether the expression of Sestrin2 in the bone marrow-derived hematopoietic compartment is important for the protective role of Sestrin2 in colitis. For this purpose, reciprocal bone marrow chimera experiments were performed: WT bone marrow was introduced into lethally irradiated *Sesn2^-/-^* mice (WT→Sn2) while *Sesn2^-/-^* bone marrow was introduced into lethally irradiated WT mice (Sn2→WT). Both groups of chimeric mice were subjected to DSS administration ([Figure 2A](#fig2){ref-type="fig"}). Interestingly, Sn2→WT mice were similar to WT mice and able to recover from DSS-induced injury ([Figure 2A,B](#fig2){ref-type="fig"}). However, more than 70% of WT→Sn2 mice were dead at 6 days following DSS treatment ([Figure 2B](#fig2){ref-type="fig"}). WT→Sn2 mice, but not Sn2→WT mice, also experienced dramatic weight loss during the recovery phase following DSS treatment ([Figure 2A](#fig2){ref-type="fig"}). Histological examination of the surviving mice revealed that, although the epithelial structure of Sn2→WT mouse colon was nearly completely restored at 6 days after the DSS treatment, WT→Sn2 colon epithelium was degenerated and marked by complete loss of epithelial cells and a robust increase in infiltrating immune cells ([Figure 2C](#fig2){ref-type="fig"}). Genotyping of spleen tissues in surviving WT→Sn2 and Sn2→WT mice confirmed that the hematopoietic compartment of recipient mice had been completely substituted with bone marrow cells of the donor ([Figure 2D](#fig2){ref-type="fig"}). These results indicate that the extra-hematopoietic presence of Sestrin2, such as in epithelial cells, is critical for the maintenance of intestinal homeostasis during colitis.10.7554/eLife.12204.006Figure 2.Sestrin2 prevents colitis-associated ER stress in colonic epithelia.(**A-D**) Sestrin2 expression in the extra-hematopoietic compartment is critical for the resolution of DSS-induced colitis. 3-month-old WT and *Sesn2^-/-^* mice (n=7 each) were subjected to lethal irradiation and injected with bone marrow cells from age-matched *Sesn2^-/-^* (Sn2→WT) and WT (WT→Sn2) mice, respectively. After 1 month, mice were subjected to DSS administration as indicated in the panel A. Body weight was measured over 15 days (**A**). Data are shown as mean ± s.e.m. Percent survival was calculated for each day (**B**). The colons of surviving mice at the final day of experiment were isolated and fixed for H&E staining (**C**). The spleens of surviving mice were genotyped for WT (upper band, \~450bp) and *Sesn2*-KO (lower band, \~200bp) alleles (**D**). (**E-H**) Loss of *Sesn2* aggravates colitis-induced ER stress in colon. Expression or phosphorylation of ER stress signaling markers were analyzed from indicated mice (described in Figure 1D-M) through immunoblotting (**E**), real-time PCR (**F**) or immunohistochemistry (**G**,**H**). Data are shown as mean ± s.e.m. \*p\<0.05, \*\*p\<0.01. *P* values are from Student's t-test. Scale bars, 200 μm (black), 100 μm (white). Molecular weight markers are indicated in bp (**D**) or kDa (**E**).**DOI:** [http://dx.doi.org/10.7554/eLife.12204.006](10.7554/eLife.12204.006)10.7554/eLife.12204.007Figure 2---figure supplement 1.Induction of ER stress and Sestrin2 upon DSS treatment.4-month-old WT mice were treated with 3% DSS in drinking water for 7 days, followed by 7 days of regular water (RW).Mice were sacrificed before the treatment (Con; n=3), right after 7 days of DSS treatment (DSS 7d only; n=5) or after completion of the experiment (DSS 7d + RW 7d; n=3). Expressions of ER stress signaling markers (**A**), inflammation markers (**B**) and Sestrin2 (**C,D**) were analyzed from indicated mice through real-time PCR (**A-C**) or immunoblotting (**D**). Data are shown as mean ± s.e.m. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. *P* values are from Student's t-test between control and indicated groups. Molecular weight markers are indicated in kDa (**D**).**DOI:** [http://dx.doi.org/10.7554/eLife.12204.007](10.7554/eLife.12204.007)10.7554/eLife.12204.008Figure 2---figure supplement 2.Increased ER stress in colon epithelia of *Sesn2^-/-^* and *Sesn2^-/-^/Sesn3^-/-^* mice during DSS-induced colon injury.Expression or phosphorylation of ER stress signaling markers were analyzed from indicated mice through immunoblotting (**A,B**), real-time PCR (**C**; n=4) or immunohistochemistry (**D,E**). Data are shown as mean ± s.e.m. \*p\<0.05. *P* values are from Student's t-test. Scale bars, 100 μm. Molecular weight markers are indicated in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.008](10.7554/eLife.12204.008)10.7554/eLife.12204.009Figure 2---figure supplement 3.Uncropped images of blots.Red boxes indicate the cropped regions. Molecular weight markers are indicated in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.009](10.7554/eLife.12204.009)

Sestrin2 deficiency impairs recovery from DSS-induced ER stress {#s2-4}
---------------------------------------------------------------

Sestrin2 protects cells and tissues from ER stress and its pathological sequelae such as metabolic abnormalities, tissue inflammation and apoptotic cell death ([@bib36]). DSS treatment was recently found to induce ER stress in colon epithelia ([@bib10]), and consistent with this report, we observed that DSS treatment can induce prolonged ER stress signaling that is associated with modestly elevated Sestrin2 expression ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Therefore, it is possible that Sestrin2 protects colon epithelium by allowing colonocytes to cope with DSS-induced ER stress insults, and thereby promoting colonic recovery after DSS injury. To test this idea, we analyzed the level of ER stress in WT and *Sesn2^-/-^* colon epithelium recovering from DSS injury. Immunoblot analyses of colon tissue showed that *Sesn2^-/-^* and *Sesn2^-/-^/Sesn3^-/-^* mice have elevated phosphorylation of pancreatic ER kinase (PERK) and increased expression of BiP and CHOP ([Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}), when compared to WT mice. mRNA expression analysis for ER stress target genes, including spliced XBP1 (XBP1s) and BiP cofactor ERdj4, were also robustly upregulated in the colon of *Sesn2^-/-^* mice ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). Immunostaining of BiP and CHOP also confirmed the presence of prominent ER stress in the damaged colon epithelium of *Sesn2^-/-^* mice ([Figure 2G,H](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2D,E](#fig2s2){ref-type="fig"}). These results collectively indicate that endogenous Sestrin2 is critical for the suppression of colon ER stress after DSS insults.

Downregulation of *SESN2* in human cancer tissues {#s2-5}
-------------------------------------------------

Our results show that Sestrin2 expression is induced during UC as a protective mechanism against colonic ER stress and epithelial degeneration. Since pre-existing colitis ([@bib49]) or tumor-elicited inflammation ([@bib21]) is important for the progression of colon cancer, it is possible that Sestrin2 expression is lost or downregulated during colon carcinogenesis. Thus, we examined the Oncomine database, which contains diverse large-scale genomic and transcriptomic analyses of normal and tumor tissues ([@bib39]), to determine if there is a differential expression of Sestrins between normal and tumor tissues. Surprisingly, in virtually all of the colon cancer transcriptome studies available within the database, which were conducted in diverse platforms using different patient tissues, human Sestrin2 (*SESN2*) mRNA expression was strongly downregulated in colon adenocarcinoma tissues when compared to normal colon controls ([Figure 3A--G](#fig3){ref-type="fig"}) ([@bib19]; [@bib20]; [@bib24]; [@bib25]; [@bib9]; [@bib47]). The magnitude of *SESN2* suppression in tumors is often among the top 1--5% of all suppressed genes ([Figure 3A](#fig3){ref-type="fig"}). Considering that these data are collected from a variety of different human samples, the extent of the difference was very strong (all studies indicate p\<10^--4^ or much lower). In contrast, other major cell type markers, such as *Villin (VIL1*, enterocytes), *DLL1* (progenitor cells), *F4/80 (EMR1*, macrophages), *Gr-1 (LY6G5B*, leukocytes), or *β-catenin (CTNNB*, colon epithelia), did not show such strong suppression ([Figure 3---figure supplement 1A--E](#fig3s1){ref-type="fig"}), while the stem cell marker *LGR5* was rather upregulated in tumor samples ([Figure 3---figure supplement 1A--E](#fig3s1){ref-type="fig"}). These results indicate that the downregulation of *SESN2* mRNA in colon cancer is specific and not an indirect consequence of different compositions of cell subtypes between normal and tumor tissues.10.7554/eLife.12204.010Figure 3.Downregulation of *SESN2* in human colon cancer tissues.(**A**) Oncomine analysis of Sestrin-family gene expression in normal and cancer tissues of different types. Gene summary views for *SESN2, SESN1* and *SESN3* genes are shown. Cell color is determined by the best gene rank percentile for the analyses within the cell, as described below the table. Thresholds for gene rank, fold change and *P* value are also described below the table. Reduction of *SESN2* in colorectal cancer tissue (highlighted in the green box) was one of the most significant alterations. (**B-G**) human *SESN2* mRNA expression in normal colon and colon cancer tissues, derived from six independent studies (**B-G**; total n=40, 78, 58, 82, 80 and 165, respectively) conducted in different platforms ([@bib19]; [@bib20]; [@bib24]; [@bib25]; [@bib9]; [@bib47]). (**H**) DNA copy number analysis of human *SESN2* gene in normal blood, normal colon and colon cancer tissues (total n=975), derived from TCGA dataset ([@bib9]). Colon cancer staging in **F**, **G** and **H** is according to the TNM staging system from the American Joint Committee on Cancer (AJCC). All data are shown as the mean ± s.e.m. *P* values between normal and cancer tissues, calculated from Student's t-test, are all below 10^--4^ (**B-H**). For TCGA dataset, *P* values between normal and cancer tissues are 1.6 x 10^--30^ (**G**) and 3.7 x 10^--58^ (**H**).**DOI:** [http://dx.doi.org/10.7554/eLife.12204.010](10.7554/eLife.12204.010)10.7554/eLife.12204.011Figure 3---figure supplement 1.Expression of cell-type specific markers in human colon cancer tissues.(**A-E**) Levels of the following mRNAs were analyzed in the studies described in [Figure 3](#fig3){ref-type="fig"}. *SESN2*, Sestrin2; *VIL1*, Villin -- Expressed in Enterocytes; *DLL1*, Delta-like 1 -- Expressed in Progenitor cells; *EMR1*, F4/80 -- Expressed in Macrophages; *LY6G5B*, Gr-1 -- Expressed in Leukocytes; *CTNNB*, β-catenin -- Expressed in Colonic Epithelia; *LGR5*, Gpr49 -- Expressed in Colonic Stem Cells. All data are shown as the mean ± s.e.m. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. N/D, not determined. *P* values were calculated from Student's t-test between normal and cancer tissues.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.011](10.7554/eLife.12204.011)

*SESN2* genome copy is also significantly reduced in colon cancer, and decreases further as the colon cancer progresses ([Figure 3H](#fig3){ref-type="fig"}). However, the extent of copy number loss was very small (\~10%), suggesting that transcriptional downregulation, rather than the loss of genomic information, is the major mechanism of *SESN2* inhibition during colon cancer progression.

*SESN2* expression exhibits strong correlation with p53 status {#s2-6}
--------------------------------------------------------------

*SESN2* is a transcriptional target of tumor suppressor p53 ([@bib8]), which is one of the most frequently mutated genes in colon cancer ([@bib14]). To test whether p53 mutation plays any role in regulating *SESN2* expression during colon carcinogenesis, we analyzed the cancer genome atlas (TCGA) dataset ([@bib9]) by partitioning tumors based on p53 status. TCGA dataset has comprehensive information regarding the genomic status of each tumor, determined by whole genome/exome sequencing. From this database, we were able to classify all the colon tumor samples into the two groups. One group, designated as \'p53-mutated\', has one or more missense or nonsense coding sequence mutations in the *TP53* gene. The second group, designated as \'p53-unknown\', is classified as such because it does not reveal any coding sequence mutations in the *TP53* gene; however, it is still possible that these tumors contain *TP53* mutations in essential non-coding regions (e.g. promoters, enhancers or introns) or other genomic or epigenetic alterations that can lead to functional p53 inactivation (e.g. MDM2 overexpression). Expressions of *SESN2* and other known p53 target genes were then analyzed in three different groups: normal colons, \'p53-unknown\' tumors and \'p53-mutated\' tumors ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).10.7554/eLife.12204.012Figure 4.Correlation between p53 status and *SESN2* expression in human colon cancer.TCGA colon/colon cancer dataset (total n=165) was partitioned according to the p53 status ([@bib9]). Normal colon tissues do not reveal any *TP53* mutation (n=19 in the dataset), while \~43% of tumor samples in the gene expression dataset (n=63 out of total 146 tumor samples), designated as \'p53-mutated\', identified missense or nonsense point mutations in the *TP53* coding region. Other tumor samples (n=83) are designated as \'p53-unknown\'. (**A**) *SESN2* expression was analyzed in indicated tissues. Data are shown as the mean ± s.e.m. \*\*p\<0.01,\*\*\*p\<0.001. *P* values were calculated from Student's t-test. (**B,C**) Expression of *SESN2* was analyzed in three different probes, and their correlations were visualized by a scatter plot of individual patient tissue samples. Trend lines were approximated through linear regression. Y axis is in a log scale. Normal colon samples are in blue, \'p53-unknown\' tumor samples are in gray, and \'p53-mutated\' tumor samples are in red. Pearson's correlation coefficients (r) with *P* values were calculated and presented. \*\*\*\*p\<0.0001. (**D-F**) Expression of *SESN2, CDKN1A, GADD45A* and *MDM2* was analyzed and their correlations were analyzed as described above for B and C. \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.012](10.7554/eLife.12204.012)10.7554/eLife.12204.013Figure 4---figure supplement 1.Correlation between p53 status and expression of *CDKN1A*, *GADD45A, MDM2, BAX, PUMA (BBC3), p53AIP1 (TP53AIP1), TSC2, AMPKβ (PRKAB1, PRKAB2*) and *PTEN* in human colon cancer.(**A-J**) Gene expression was analyzed in indicated tissues, using the same dataset as in [Figure 4](#fig4){ref-type="fig"}. The data are shown as the mean ± s.e.m. NS, not significant; \*p\<0.05, \*\*\*p\<0.001. *P* values were calculated from Student's t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.013](10.7554/eLife.12204.013)

The analyses demonstrated that *SESN2* expression is significantly reduced in \'p53-mutated\' tumors when compared to \'p53-unknown\' tumors ([Figure 4A](#fig4){ref-type="fig"}), suggesting a role of p53 in controlling *SESN2* expression. This reduction was consistently observed in three independent *SESN2* probes ([Figure 4A--C](#fig4){ref-type="fig"}). Strikingly, there were almost no overlaps of *SESN2* expression levels between the normal colon and \'p53-mutated\' tumor groups ([Figure 4B,C](#fig4){ref-type="fig"}), while *SESN2* levels in \'p53-unknown\' tumors overlap with both groups ([Figure 4B,C](#fig4){ref-type="fig"}). Other known p53 target genes, such as *CDKN1A (p21), GADD45A* and *MDM2* ([@bib40]), did not show this strong correlation: for these genes, considerable overlaps were found between the normal colon and \'p53-mutated\' tumor groups in individual samples ([Figure 4D--F](#fig4){ref-type="fig"}). Nevertheless, expression levels of these genes have a general positive correlation with expression of *SESN2* in individual samples ([Figure 4D--F](#fig4){ref-type="fig"}), suggesting that *SESN2, CDKN1A, GADD45A* and *MDM2* are all regulated through the same p53-dependent mechanism. Indeed, all of these genes are differentially expressed between \'p53-unknown\' and \'p53-mutated\' tumor groups ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}).

Interestingly, some p53 target genes, such as apoptosis mediators *BAX, PUMA (BBC3*) and *p53AIP1 (TP53AIP1*) ([@bib40]) or mTORC1 regulators *TSC2*, *AMPKβ (PRKAB1* and *PRKAB2*) and *PTEN* ([@bib16]), did not show differential expression between the \'p53-unknown\' and \'p53-mutated\' tumor groups ([Figure 4---figure supplement 1D--J](#fig4s1){ref-type="fig"}), suggesting that the effects of p53 mutations on these genes are minimal in the pathological context of colon carcinogenesis.

These results collectively highlight *SESN2* as a clinically relevant target of p53 during colon carcinogenesis.

*Sesn2* loss promotes colitis-induced colon cancer growth {#s2-7}
---------------------------------------------------------

To more precisely establish the cause-effect relationship between Sestrin2 and colon cancer development, *Sesn2^-/-^* mice were further assessed. The analysis of two-year-old WT and *Sesn2^-/-^* mice (n=6 each) did not reveal any noticeable colon tumors, suggesting that *Sesn2* may not be a classical tumor suppressor gene whose homozygous deletion is sufficient to induce spontaneous cancer development. However, given the strong correlation between *SESN2* expression and colon cancer tumorigenesis in humans ([Figure 3](#fig3){ref-type="fig"}), we reasoned that endogenous Sestrin2 may play a role in attenuating tumor development and progression. Thus, *Sesn2^-/-^* mice were subjected to an established protocol of colitis-associated colon cancer induction; in this model, colon carcinogenesis is initiated by azoxymethane (AOM) administration and promoted by repeated colon injury induced by 2.5% DSS. However, none of *Sesn2^-/-^* mice (n=7) survived the first round of colitis induction ([Figure 5A](#fig5){ref-type="fig"}), while WT mice were able to survive the entirety of the treatment. This is consistent with our findings that Sestrin2 has an important physiological role in maintaining epithelial integrity during colon injury ([Figures 1](#fig1){ref-type="fig"}--[2](#fig2){ref-type="fig"}).10.7554/eLife.12204.014Figure 5.Loss of *Sesn2* promotes colon tumor growth in mice.(**A**) 2-month-old WT and *Sesn2^-/-^* mice were exposed to a standard protocol of azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced colon carcinogenesis as outlined in this figure panel. However, none of the *Sesn2^-/-^* mice (n=7) survived after the first round of administration of DSS , suggesting that they are hypersensitive to DSS-induced colitis. (**B**) WT and *Sesn2^-/-^* mice (n=11 each) were subjected to a modified protocol of AOM-DSS-induced colon cancer. By reducing the dose of DSS to 1.5%, we were able to keep a substantial number of *Sesn2^-/-^* mice (n=9) alive until the experimental endpoint. Tumor incubation period was extended to 100 days to compensate for the lower dose of DSS treatment. (**C-G**) After completion of the experiment, colons were examined under a dissection microscope (**C**), and tumor number (**D**), average tumor size (**E**), size of individual tumors (**F**) and total tumor burden (**G**) were analyzed and presented as means from each mouse and as mean ± s.d. of the whole groups. (**H-N**) Sestrin2-deficient tumors exhibit increased proliferation. Colon tumor (**T**) and normal colon (**N**) tissues of indicated mice were subjected to immunohistochemistry of β-catenin (**H**), PCNA (**I**) and γ-H~2~AX (**J**) or TUNEL staining (**K**). PCNA- (**L**), γ-H~2~AX- (**M**) and TUNEL-positive (**N**) cells from indicated tissues were quantified and presented as mean ± s.e.m. NS, not significant; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. *P* values are from Student's t-test. Scale bars, 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.014](10.7554/eLife.12204.014)

To overcome the DSS-induced lethality of *Sesn2^-/-^* mice, a lower dose of DSS (1.5%) was administered to both control and experimental groups in the colitis-associated cancer model ([Figure 5B](#fig5){ref-type="fig"}). This modification enabled both WT and *Sesn2^-/-^* groups to survive through three inflammatory and recovery phases, and develop macroscopically visible colon tumors at 100 days after AOM injection ([Figure 5C](#fig5){ref-type="fig"}). There was no substantial difference in the number of tumors between WT and *Sesn2^-/-^* mice ([Figure 5D](#fig5){ref-type="fig"}). However, tumor size ([Figure 5E,F](#fig5){ref-type="fig"}) and burden ([Figure 5G](#fig5){ref-type="fig"}) were dramatically increased in *Sesn2^-/-^* mice, suggesting that Sestrin2 loss promoted tumor growth and progression in the colitis-associated cancer model. Tumors developed in both WT and *Sesn2^-/-^* mice displayed classical characteristics of colon adenomas, such as nuclear β-catenin staining ([Figure 5H](#fig5){ref-type="fig"}), increased cell proliferation ([Figure 5I](#fig5){ref-type="fig"}; PCNA staining), DNA damage ([Figure 5J](#fig5){ref-type="fig"}; γ-H2AX staining) and apoptotic cell death ([Figure 5K](#fig5){ref-type="fig"}; TUNEL staining). Quantification of PCNA-, γ-H2AX- and TUNEL-positive cells showed that tumor cell proliferation ([Figure 5L](#fig5){ref-type="fig"}) is significantly increased in tumors isolated from *Sesn2^-/-^* mice, while DNA damage ([Figure 5M](#fig5){ref-type="fig"}) and apoptosis ([Figure 5N](#fig5){ref-type="fig"}) were not significantly altered by the loss of Sestrin2.

Sestrin2 suppresses tumor growth in the extra-hematopoietic compartment {#s2-8}
-----------------------------------------------------------------------

Using the reciprocal bone marrow chimera experiments followed by the AOM-DSS treatments ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), we assessed whether the expression of Sestrin2 in the hematopoietic or extra-hematopoietic compartment is important for the tumor-suppressive role of Sestrin2 in colon cancer. Compared to the Sn2→WT mice, WT→Sn2 mice exhibited strongly exacerbated tumor growth phenotypes, which was evident in both tumor number and size ([Figure 6A--D](#fig6){ref-type="fig"}), indicating that the extra-hematopoietic expression of Sestrin2, such as in colon epithelia, is critical for colon tumor suppression.10.7554/eLife.12204.015Figure 6.Sestrin2 loss increases mTORC1 signaling in colon cancer.(**A-D**) 3-month-old WT and *Sesn2^-/-^* mice (n=11 each) were subjected to lethal irradiation and injected with bone marrow cells from age-matched *Sesn2^-/-^* (Sn2→WT) and WT (WT→Sn2) mice, respectively. After 1 month, mice were subjected to AOM/DSS administration as indicated in [Figure 5B](#fig5){ref-type="fig"}. After completion of the experiment, colons were examined under a dissection microscope (**A**), and tumor number (**B**), colon length (**C**) and tumor size (**D**) were analyzed and presented as mean ± s.e.m. (**E, F** and **J**) Colon tumor (T) and normal colon (N) tissues of indicated mice were subjected to immunohistochemistry of phospho-Ser235/236-S6 (**E** and **J**) or phospho-Thr37/46-4E-BP (**F**). (**G-I**, **K** and **L**) Colon tumor (T) and normal colon (NT) tissues of WT and *Sesn2^-/-^* (S2) mice (**G-I**), as well as WT→Sn2 and Sn2→WT mice (**K** and **L**), were subjected to immunoblotting of indicated mTORC1 and mTORC2 signaling markers (**G** and **K**). Relative band intensities were quantified through densitometry and presented as mean ± s.e.m (**H, I** and **L**; n=6 in each group). \*p\<0.05, \*\*\*p\<0.001. *P* values are from Student's t-test. Scale bars, 200 μm. Molecular weight markers are indicated in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.015](10.7554/eLife.12204.015)10.7554/eLife.12204.016Figure 6---figure supplement 1.Efficiency of bone marrow transplantation.Spleen tissues from S2→WT (**A**) and WT→S2 (**B**) mice described in [Figure 6](#fig6){ref-type="fig"} were genotyped for WT (upper band, \~450bp) and *Sesn2*-KO (lower band, \~200bp) alleles. Molecular weight markers are indicated in bp.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.016](10.7554/eLife.12204.016)10.7554/eLife.12204.017Figure 6---figure supplement 2.Additional immunohistochemistry results for [Figure 6E](#fig6){ref-type="fig"} (**A**), [Figure 6F](#fig6){ref-type="fig"} (**B**) and [Figure 6J](#fig6){ref-type="fig"} (**C**).Colon tumor (T) and normal colon (N) tissues of indicated mice were subjected to immunohistochemistry of phospho-Ser235/236-S6 (**A** and **C**) or phospho-Thr37/46-4E-BP (**B**). Scale bars, 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.017](10.7554/eLife.12204.017)10.7554/eLife.12204.018Figure 6---figure supplement 3.Additional immunoblotting results for [Figure 6G](#fig6){ref-type="fig"} (**A**) and [Figure 6K](#fig6){ref-type="fig"} (**B**).Colon tumor (T) and normal colon (NT) tissues of WT and *Sesn2^-/-^* (S2) mice (**A**), as well as WT→Sn2 and Sn2→WT mice (**B**), were subjected to immunoblotting of indicated mTORC1 and mTORC2 signaling markers. Molecular weight markers are indicated in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.018](10.7554/eLife.12204.018)10.7554/eLife.12204.019Figure 6---figure supplement 4.Uncropped images of blots.Red boxes indicate the cropped regions. Molecular weight markers are indicated in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.019](10.7554/eLife.12204.019)

*Sesn2* loss induces mTORC1 hyperactivation {#s2-9}
-------------------------------------------

It is possible that epithelial Sestrin2 expression tissue-autonomously suppresses colon tumor growth. Indeed, Sestrin2 is a potent inhibitor of mTORC1 ([@bib6]; [@bib29]), which is known to be critical for tumorigenic growth in colon cancer cells ([@bib13]; [@bib22]). Therefore, we analyzed mTORC1 downstream target proteins in colon cancer and normal colon tissues from WT and *Sesn2^-/-^* mice through immunohistochemistry. Phosphorylation of ribosomal protein S6, which is mediated by an mTORC1 target p70 S6 kinase (S6K), is dramatically increased in tumors isolated from *Sesn2^-/-^* mice ([Figure 6E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). Consistent with this observation, phosphorylation of eukaryotic translation initiation factor 4E-binding protein (4E-BP), an additional mTORC1 target, was also prominently increased in *Sesn2^-/-^* colon cancer tissues, when compared to adjacent normal colon tissues as well as to WT colon cancer tissues ([Figure 6F](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). These immunohistochemical observations were also confirmed by immunoblotting experiments; S6 and 4E-BP phosphorylation was prominently increased in colon tumors of *Sesn2^-/-^* mice, compared to those of WT mice ([Figure 6G--I](#fig6){ref-type="fig"} and [Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}). Tumors from WT→Sn2 mice, but not those from Sn2→WT mice, also exhibited hyperactive mTORC1 signaling, indicated by increased S6 phosphorylation ([Figure 6J--L](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"},[3B](#fig6s3){ref-type="fig"}). However, AKT Ser473 phosphorylation, which is mediated by mTORC2, a complex distinct from mTORC1, was not significantly altered by Sestrin2 loss in colon cancer tissues ([Figure 6G](#fig6){ref-type="fig"}). Collectively, these data suggest that Sestrin2 loss selectively leads to mTORC1 hyperactivation in colon cancer tissues, which subsequently allowed for prominent tumor overgrowth.

p53 regulates Sestrin2 expression in colon cancer cells {#s2-10}
-------------------------------------------------------

Unlike human colon cancer tissues ([Figures 3](#fig3){ref-type="fig"},[4](#fig4){ref-type="fig"}), mouse colon cancers induced by the AOM-DSS treatment displayed Sestrin2 expression at a level comparable to that of normal colon tissues ([Figure 6G](#fig6){ref-type="fig"}). The expression of Sestrin2 in mouse colon tumor cells may provide an explanation for the relatively low mTORC1 activity in the tumors ([Figure 6E--L](#fig6){ref-type="fig"}) that do not progress to adenocarcinomas ([@bib43]). Interestingly, it has been formerly reported that most mouse colon tumors induced by the AOM-DSS treatment do not contain p53 mutations or misregulation ([@bib32]; [@bib48]), and this may provide an explanation of why Sestrin2 expression is sustained in this specific mouse model of colon cancer. Indeed, SW480 cells, a human colon cancer cell line that displays very low p53 activity, demonstrated a strong downregulation of Sestrin2 expression, while RKO and HCT116 cells, which have wild-type p53 activity, expressed a relatively high amount of Sestrin2 proteins ([Figure 7A](#fig7){ref-type="fig"}). The p53-deficient HCT116 cells exhibited dramatic downregulation of Sestrin2 expression when compared to the parental HCT116 cells ([Figure 7B](#fig7){ref-type="fig"}). Expression of Sestrin2 in hyperplastic mouse colon tissues, which have mutations in both *Apc* and *Kras* genes ([@bib15]), was also reduced by the loss of p53 or a dominant-negative mutation of p53 ([Figure 7C](#fig7){ref-type="fig"}). Consistent with clinical data on human *SESN2* expression described above ([Figure 4](#fig4){ref-type="fig"}), these results further support the notion that p53 is critical for Sestrin2 expression in colon cancer cells.10.7554/eLife.12204.020Figure 7.p53 controls mTORC1 signaling through Sestrin2 in colon cancer cells.(**A-F**) Whole cell or tissue lysates from the following experiments were subjected to immunoblotting of indicated proteins. (**A**) Human colon cancer cell lines (RKO, HCT116 and SW480) were serum-starved for 24 hr and then treated with 10% FBS (serum) for 2 hr. (**B**) *p53*-knockout (HCT116 *p53^-/-^*) and control HCT116 cells were serum-starved for 24 hr and then treated with 10% FBS for indicated time. (**C**) *CDX2P-CreER^T2^Apc^flox/flox^ Kras^LSL-G12D/+^ p53^flox/flox^* (left three lanes)*, CDX2P-CreER^T2^Apc^flox/flox^ Kras^LSL-G12D/+^ p53^+/+^* (centre three lanes), and *CDX2P-CreER^T2^Apc^flox/flox^ Kras^LSL-G12D/+^ p53^R270H/+^* (right three lanes) mice ([@bib15]) were daily injected with 100 mg/kg tamoxifen (i.p.) for 3 days, and dysplastic colon tissues were harvested after 8 days. (**D**) HCT116 *p53^-/-^* cells were infected with GFP- or Sestrin2-expressing lentiviruses. After 24 hr, cells were serum-starved for 24 hr and treated with 10% FBS for indicated time. (**E**) SW480 cells were infected with GFP- or Sestrin2-expressing lentiviruses. After 24 hr, cells were serum-starved for 24 hr and treated with 10% FBS for indicated time. (**F**) RKO cells, stably infected with lentiviruses expressing shRNA targeting luciferase (sh-*Luc*) or the *SESN2* (sh-*SESN2*) gene, were serum-starved for 24 hr and then treated with 10% FBS for indicated time. Molecular weight markers are indicated in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.020](10.7554/eLife.12204.020)10.7554/eLife.12204.021Figure 7---figure supplement 1.Sestrin2 inhibits colon cancer cell growth through mTORC1 inhibition.(**A** and **B**) RKO cells, stably infected with lentiviruses expressing shRNA targeting luciferase (sh-*Luc*) or the *SESN2* (sh-*SESN2*) gene, were subjected to colony-forming assay. In brief, cells were seeded sparsely (1000 cells per well for 6-well plates) and grown for 10 days in normal medium with or without rapamycin (Rap, 20 nM). Colonies were fixed in methanol and stained with 0.1% crystal violet (C581, Fisher Scientific). The plates were imaged under EPSON Perfection V30 scanner (**A**). Relative colony growth was determined by densitometry of stained images (**B**; n=3 from three different plates per group). (**C** and **D**) SW480 cells were infected with lentiviruses expressing *GFP* or *SESN2*. At 24 hr after the infection, the cells were subjected to a colony-forming assay as described above (n=3). All data are shown as the mean ± s.e.m. \*p\<0.05, \*\*p\<0.01. *P* values are from Student's t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.021](10.7554/eLife.12204.021)10.7554/eLife.12204.022Figure 7---figure supplement 2.Sestrin2-deficiency renders cancer cells less sensitive to chemotherapy.(**A-C**) RKO cells, stably infected with lentiviruses expressing shRNA targeting luciferase (sh-*Luc*) or the *SESN2* (sh-*SESN2*) gene, were subjected to colony-forming assay. In brief, cells were seeded sparsely (1000 cells per well for 6-well plates), treated with 5-fluorouracil (5-FU, 1 μM) and irinotecan (CPT-11, 10 μM) as indicated for 24 hr, and grown for 14 days in normal medium. Colonies were fixed in methanol and stained with 0.1% crystal violet (C581, Fisher Scientific). The plates were imaged under EPSON Perfection V30 scanner (**A**). Relative colony growth was determined by densitometry of stained images (**B**; n=3 from three different plates per group), and the growth suppression effects of 5-FU and CPT-11 were calculated from the densitometry results (**C**; n=3 from three different plates per group). (**D**,**E**) RKO cells, stably infected with sh-*Luc* or sh-*SESN2* gene, were treated with indicated concentrations (μM) of 5-FU and CPT-11 for 24 hr and subjected to immunoblotting of indicated proteins. (**F**) Current model of how Sestrin2 suppresses colon cancer progression. During colitis, Sestrin2 promotes restoration of colon homeostasis after injury through limiting ER stress. However, during carcinogenesis, p53 is inactivated and Sestrin2 expression is downregulated, which subsequently causes hyperactivation of mTORC1 signaling and promotes colon cancer development and growth. The p53-Sestrin2 axis may also be important for the effect of chemotherapy in attenuating colon cancer growth. All data are shown as the mean ± s.e.m. \*p\<0.05, \*\*p\<0.01. *P* values are from Student's t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.022](10.7554/eLife.12204.022)10.7554/eLife.12204.023Figure 7---figure supplement 3.Uncropped images of blots.Red boxes indicate the cropped regions. Molecular weight markers are indicated in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.12204.023](10.7554/eLife.12204.023)

Sestrin2 suppresses clonogenic growth through mTORC1 inhibition {#s2-11}
---------------------------------------------------------------

p53 inhibits mTORC1 signaling, and this regulation may be an important contributor to the tumor suppressive activity of p53 ([@bib1]; [@bib17]). To understand if Sestrin2, acting as a p53 target, has an essential role in regulating mTORC1 and colon cancer cell growth, Sestrin2 was overexpressed in p53-deficient HCT116 cells and SW480 cells, which have low *SESN2* expression and high mTORC1 signaling ([Figure 7A,B](#fig7){ref-type="fig"}). Restoration of Sestrin2 suppressed serum-induced phosphorylation of mTORC1 substrates, S6K and 4E-BP ([Figure 7D,E](#fig7){ref-type="fig"}), but not mTORC2 substrate AKT ([Figure 7E](#fig7){ref-type="fig"}). Sestrin2 silencing in RKO cells enhanced the mTORC1 signaling in both starved and serum-stimulated cells ([Figure 7F](#fig7){ref-type="fig"}), indicating that endogenous Sestrin2 indeed functions to inhibit mTORC1 signaling in human colon cancer cells.

As mTORC1 is known to control cell growth, we examined the effect of Sestrin2 on clonogenic growth of RKO and SW480 cells. A colony forming assay of Sestrin2-silenced RKO cells demonstrated an increase in clonogenic growth compared to the control cells ([Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}), suggesting that Sestrin2 is an inhibitor of cancer cell growth. To further investigate if this Sestrin2 activity is dependent on mTORC1 hyperactivation, we treated control and Sestrin2-silenced cells with rapamycin, an inhibitor of mTORC1. Rapamycin inhibited clonogenic growth in both control and Sestrin2-silenced cells, and interestingly, the growth difference between control and Sestrin2-silenced cells was diminished upon rapamycin treatment ([Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}). These results indicate that Sestrin2 attenuates cancer cell growth primarily through inhibition of a hyperactive mTORC1. On the other hand, expression of Sestrin2 in SW480 cells substantially inhibited clonogenic growth ([Figure 7---figure supplement 1C,D](#fig7s1){ref-type="fig"}), supporting the idea that Sestrin2 is critical for inhibition of colon cancer cell overgrowth.

Sestrin2 loss confers chemotherapy resistance to colon cancer cells {#s2-12}
-------------------------------------------------------------------

As a stress-inducible cell growth regulator, Sestrin2 may be also important for the responsiveness of colon cancer cells to chemotherapeutic treatments. To examine this possibility, we treated control and Sestrin2-silenced RKO cells with two representative chemotherapeutic agents, 5-fluorouracil (5-FU) and irinotecan (CPT-11). Although control cell growth was strongly suppressed by 5-FU or CPT-11, Sestrin2 silencing rendered cells less susceptible to the chemotherapeutic drug treatments ([Figure 7---figure supplement 2A--C](#fig7s2){ref-type="fig"}), suggesting that Sestrin2 loss may confer chemotherapy resistance to colon cancer cells.

We also examined Sestrin2 expression and mTORC1 signaling in RKO cells when treated with 5-FU and CPT-11. After 5-FU or CPT-11 treatments, Sestrin2 expression was slightly elevated in WT cells (sh-Luc; [Figure 7---figure supplement 2D,E](#fig7s2){ref-type="fig"}). Interestingly, mTORC1 signaling, monitored by p-S6K and p-4E-BP1, was prominently upregulated in sh-*SESN2* cells after 5-FU treatment ([Figure 7---figure supplement 2D](#fig7s2){ref-type="fig"}), suggesting that Sestrin2 suppresses mTORC1 activation after 5-FU treatment. In contrast, CPT-11 treatment reduced mTORC1 signaling, and Sestrin2 silencing led to modest but persistent mTORC1 upregulation ([Figure 7---figure supplement 2E](#fig7s2){ref-type="fig"}). This mTORC1 upregulation as a result of Sestrin2 loss could have conferred chemoresistance to RKO cells against 5-FU and CPT-11.

Discussion {#s3}
==========

The current study reveals how the stress-inducible protein Sestrin2 can coordinate ER stress and mTORC1 signaling pathways to maintain epithelial homeostasis and limit colitis and colon cancer development during colon injury ([Figure 7---figure supplement 2F](#fig7s2){ref-type="fig"}). Yet, it is still possible that the mechanisms underlying increased susceptibility to colitis and colon cancer are separate from each other. During colitis stress, Sestrin2 functions to suppress ER stress and to promote regeneration of colon epithelium ([Figures 1](#fig1){ref-type="fig"},[2](#fig2){ref-type="fig"}). However, Sestrin2 expression is lost during human colon carcinogenesis ([Figure 3](#fig3){ref-type="fig"}) through inactivation of tumor suppressor p53 ([Figures 4](#fig4){ref-type="fig"},[7](#fig7){ref-type="fig"}). Because expression of Sestrin2 is important for suppressing hyperactive mTORC1 signaling ([Figure 6](#fig6){ref-type="fig"}) and tumor outgrowth ([Figure 5](#fig5){ref-type="fig"}), loss of Sestrin2 expression in human colon cancer serves as a critical tumorigenic mechanism. Indeed, Sestrin2 negatively controlled cell growth in various human colon cancer cell lines, which was dependent on mTORC1 regulation ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Furthermore, inactivation of Sestrin2 conferred chemoresistance to colon cancer cells ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}), rendering them difficult to treat with conventional chemotherapeutic methods.

In addition to mTORC1 regulation, Sestrin2 is also known to reduce oxidative stress ([@bib7]) by functioning as an activator of anti-ROS transcription factor Nrf2 ([@bib3]) or as an alkylhydroperoxidase ([@bib27]). Thus, it is possible that the loss of Sestrin2 can contribute to cellular accumulation of ROS, which can promote DNA damage and genomic mutations that facilitate tumor development ([@bib44]). However, analysis of γ-H2AX did not show a significant increase in DNA damage between colon tumors of WT and *Sesn2^-/-^* mice ([Figure 5J,M](#fig5){ref-type="fig"}). This result suggests that the mTORC1-regulatory function, rather than the ROS-inhibiting function, is the main contributor of Sestrin2's tumor suppressive activity in colon tissues. Nevertheless, it is still possible that Sestrin2 attenuates tumor growth, at least partially by inhibiting tumor-associated epithelial damage and inflammation ([Figures 1](#fig1){ref-type="fig"},[2](#fig2){ref-type="fig"}), which are well-characterized promoters of colon cancer growth ([@bib21]; [@bib49]). It is also possible that Sestrin2 exerts tumor suppressive activity additionally through its apoptosis-inducing function, which was recently discovered ([@bib12]).

The mTORC1-suppressing and ROS-reducing activities are shared between all members of the Sestrin family (Sestrin1-3) ([@bib29]; [@bib33]). However, only Sestrin2 was shown to be downregulated in human colon cancer tissues, and expression of Sestrin1 and Sestrin3 was unchanged or slightly upregulated in the colon cancer tissues. Nevertheless, Sestrin1 and Sestrin3 are strongly downregulated in several types of cancer tissues, such as lung cancers and lymphomas ([Figure 3A](#fig3){ref-type="fig"}), suggesting that they may be involved in anti-tumorigenic processes in tissues other than the colon. *Drosophila* Sestrin, which is the only Sestrin homologue expressed in *Drosophila*, was formerly shown to be a feedback inhibitor of mTORC1, which can suppress hyperplastic tissue growth provoked by oncogenic mTORC1 hyperactivation ([@bib30]). As the current study demonstrates Sestrin2 to be an inhibitor of colon cancer growth, future studies on the role of Sestrin1 and Sestrin3 in carcinogenic processes of other tissues may reveal a conserved tumor-suppressive role of Sestrin-family proteins.

Materials and methods {#s4}
=====================

Antibodies and reagents {#s4-1}
-----------------------

For immunoblotting, we obtained S6K (sc-230), PERK (sc-13073) and p-PERK (sc-32577) antibodies from Santa Cruz Biotechnology, Dallas, TX, human Sestrin2 (10795-1-AP) antibody from Proteintech, Chicago, IL, BiP (3177), CHOP (2895), p-Thr389 S6K (9234), p-Ser235/236 S6 (2211), S6 (2317), p-Thr37/46 4E-BP (2855), 4E-BP (9452), p-Ser473 AKT (9273) and AKT (4691) antibodies from Cell Signaling Technology, Danverse, MA, actin (JLA20) antibody from Developmental Studies Hybridoma Bank (DSHB, Iowa city, IA), and tubulin (T5168) antibody from Sigma, St. Louis, MO. Mouse Sestrin2 antibody was described ([@bib42]). For immunostaining, we obtained p53 (sc-6243), PCNA (sc-7907), β-catenin (sc-59737), CHOP (sc-575) from Santa Cruz Biotechnology, F4/80 (mf48000) from Invitrogen, Carlsbad, CA, BiP (3177), γ-H2AX (2577), p-Ser235/236 S6 (2211) and p-Thr37/46 4E-BP (2855) from Cell Signaling Technology. Azoxymethane (AOM), dextran sulfate sodium (DSS), rapamycin, 5-fluorouracil (5-FU) and irinotecan (CPT-11) were from Sigma.

Cell culture {#s4-2}
------------

Human colon cancer cell lines, including RKO, SW480 and HCT116, were obtained from American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS, Sigma), 50 U/ml penicillin and 50 mg/ml streptomycin. The cells were authenticated by Short Tandem Repeat (STR) profiling at ATCC, tested negative for mycoplasma infection, and subcultured for less than 6 months prior to initiation of the described experiments. *p53*-knockout HCT116 cells were obtained from Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD). The p53 loss in this cell line was confirmed by western blot. All cultures were maintained in a 37°C incubator with 5% CO~2~. The lentiviral constructs for Sestrin2 overexpression and silencing are formerly described ([@bib6]). Viruses were generated and amplified in the Vector Core facility at the University of Michigan (UM).

Immunoblotting {#s4-3}
--------------

Cells and tissues were lysed in RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% NP-40; 0.1% SDS) or cell lysis buffer (20 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na~3~VO~4~, 1% Triton-X-100) containing protease inhibitor cocktail (Roche, Indianapolis, IA), and processed as formerly described ([@bib41]). Protein samples were boiled in SDS sample buffer for 5 min, separated by SDS-PAGE, transferred to PVDF membranes and probed with primary antibodies (1:200 for Santa Cruz antibodies, and 1:1000 for all other antibodies). After incubation with secondary antibodies conjugated with HRP (Bio-rad; 1:2000), chemiluminescence was detected using LAS4000 (GE, Fairfield, CT) systems or X-ray films. Immunoblot images were quantified by densitometry, and protein expressions were presented as relative band intensities. Uncropped images of immunoblots are provided in [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"} and [Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}.

Quantitative reverse transcriptase-real time PCR {#s4-4}
------------------------------------------------

Total RNA was extracted from tissues or cells using Trizol reagent (Invitrogen), and cDNA was made using MMLV-RT (Promega, Madison, WI) and random hexamers (Invitrogen). Quantitative PCR was performed in a Real-Time PCR detection system (Applied Biosystems, Foster city, CA) with iQTM SYBR Green Supermix (Bio-rad, Hercules, CA) and relevant primers. Relative mRNA expression was calculated from the comparative threshold cycle (Ct) values relative to *β-Actin*. Primers for *Sestrins*, inflammation markers (*Tnfa, Il6, Il1b* and *Il10*), ER stress markers (*Xbp1s, ERdj4, Gadd34, Ero1α, Edem1,* and *Pdi*) and *β-Actin* were formerly described ([@bib35]; [@bib36]; [@bib41]).

Database analyses {#s4-5}
-----------------

mRNA expression data and genome copy data from various studies were retrieved from Oncomine database ([@bib39]). Exome sequencing information regarding the status of p53 was retrieved from Supplmentary Table 2 of TCGA colon cancer paper ([@bib9]). TCGA data, retrieved from Oncomine, were manually partitioned into \'p53-mutated\' and \'p53-unknown\' groups according to the p53 gene status. When multiple probes for a same gene were found from the database, probes whose average values between normal and cancer groups (or between normal and \'p53-mutated\' groups) are close to zero in log scale were selected for further analysis. Bar graphs were plotted in a linear scale and control values were normalized to one. Scatter plots were presented in a logarithmic scale using raw data. Correlation and linear regression analyses were performed in Graphpad Prism 6.

Animal experiments {#s4-6}
------------------

WT, *Sesn2^-/-^* and *Sesn2^-/-^/Sesn3^-/-^* mice ([@bib31]) and *CDX2P-CreER^T2^Apc^flox/flox^*mice ([@bib15]) were used for this study. These mice are on a C57BL/6 background. Mice were maintained in filter-topped cages and given free access to autoclaved regular chow diet at the UM according to the NIH and institutional guidelines. All animal studies were ethically approved (protocol approval numbers: PRO00005712 and PRO00004019) and overseen by the University Committee on Use and Care of Animals (UCUCA) at the UM.

For colitis induction, mice received water with 3% DSS for 6--7 days (inflammatory phase). Then the mice were placed on regular drinking water for 5--7 days (recovery phase) as formerly described ([@bib56]). For tumor induction, mice were treated with AOM (10 mg/kg body weight). At 5 days following the AOM injection, mice received water with 1.5% DSS for 7 days (inflammatory phase). Then, the mice were placed on regular drinking water for 14 days (recovery phase). The mice were subjected to two more inflammatory and recovery cycles for tumor induction as in [Figure 5A,B](#fig5){ref-type="fig"}. Reciprocal bone marrow chimera experiments were done as described in our recent paper ([@bib2]), and the mice were subjected to DSS or AOM/DSS treatment at 1 month after the bone marrow transplantation to allow for complete substitution of the hematopoietic compartment. The mice in the same experiments are from an age-matched, co-housed cohort, and animal numbers were determined according to our previous studies ([@bib2]; [@bib56]).

Colon tumor phenotyping {#s4-7}
-----------------------

A dissecting microscope (4x magnification) was used to assess the tumor number and size. Tumor size was defined as the mean of the two largest diameters measured with digital calipers. Tumor volume was derived from tumor size. Consistent with their histological appearance, a spherical shape was assumed for colon polyps, thus tumor volume = 4/3πr^3^, where r = radius. Tumor burden/load is defined as the total polyp volume per animal, which is the product of polyp number and polyp volume.

Histology {#s4-8}
---------

Colons were removed, flushed with PBS, fixed in 4% paraformaldehyde at 4°C overnight and paraffin-embedded for histological analyses. Antigen retrieval was performed in 10 mM sodium citrate at 95°C for 15 min. For immunostaining of PCNA, β-catenin, F4/80, BiP, γ-H2AX, p-Ser235/236 S6 and p-Thr37/46 4E-BP, colon sections were incubated with corresponding primary antibodies (1:50, 1:50, 1:100, 1:200, 1:50, 1:200 and 1:100, respectively), followed by incubation with biotin-conjugated secondary antibodies (1:200) and streptavidin-HRP (1:300). The HRP activity was visualized with diaminobenzidine staining. Haematoxylin counterstaining was applied to visualize nuclei. For immunostaining of CHOP, colon sections were incubated with primary antibody (1:50), followed by incubation with Alexa 594-conjugated secondary antibody. DAPI counterstaining was applied to visualize nuclei. TdT-mediated dUTP nick end labeling (TUNEL) assay was performed using In Situ Cell Death Detection Kit TMR-Red (1215792910, Roche). The samples were analysed under an epifluorescence-equipped light microscope (Meiji MT6300).
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2010,Data from: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability,<https://www.oncomine.com>,PMID: 20957034
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Tumor suppressive role of Sestrin2 during colitis and colon carcinogenesis\" for consideration by *eLife*. Your article has been favorably evaluated by Tony Hunter (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The current paper by Ro et al. demonstrates a tumor suppressive role for the SESN2 gene in colorectal cancer. Using a plethora of complementary approaches, the authors propose that loss of SESN2 is a key event during the development of colorectal cancer. The paper includes a number of mechanistic investigations depicting a tumor suppressive pathway whereby stress induces p53, which then induces SESN2, which then represses mTOR activity to suppress tumor growth.

The reviewers discussed the manuscript and decided to encourage resubmission of a revised manuscript addressing several major concerns:

1\) [Figure 1A-C](#fig1){ref-type="fig"}: It is not clear where these samples were obtained from and how they were analyzed. What was used as a control? Although there was a trend for mRNA increase of Sesn2 and Sesn3 in patients (n=10), the error bar is pretty big, which makes the data weak. If the authors really want to make this point, more patients samples are needed.

2\) [Figure 1D](#fig1){ref-type="fig"}. According to the working hypothesis, Sesn2 protects from ER stress and inflammation. Nevertheless, there is no significant difference between 2 mouse strains in body weight during first 7 days of treatment indicating that Sesn2 is not directly involved in control of inflammation and the observed phenotype might be a residual effect of Sesn2 inactivation. The effects of Sesn2 have to be assessed immediately after DSS treatment, and the impact of the DSS treatment on tissue morphology, regulation of Sesn2 protein expression, mTORC1 activity, ER stress levels and the inflammation should be addressed.

3\) The mice used in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} are different ages and are not comparable. It is not clear why the authors used 6-month old mice in [Figure 1](#fig1){ref-type="fig"} rather than the younger mice as in [Figure 2](#fig2){ref-type="fig"}. Please clarify.

4\) In [Figure 2E](#fig2){ref-type="fig"}/F only DSS-treated mice are analyzed. To prove their claim the authors should compare the levels of ER stress in untreated and DSS-treated mice analyzing Sesn2 expression and the expression of the ER markers. Moreover, the protein extracts were not well normalized in [Figure 2E](#fig2){ref-type="fig"} and the actin marker is overexposed. Also the role of Sesn2 and ER stress in regulation of cell death is not addressed directly and not quantitated.

5\) [Figure 3](#fig3){ref-type="fig"}: The subtle difference in mRNA levels between normal tissue and in tumors can be explained by compositions of different cell types in normal and tumor samples. Surprisingly, there is no significant downregulation of Sesn2 expression during cancer progression. Did the authors carry out an analysis of Sesn2 locus to find if Sesn2 locus has undergone LOH in tumors? Also related to this figure, unlike TP53, which is mutated in about half of all colorectal cancers, SESN2 is rarely mutated. The authors mined several public datasets demonstrating that SESN2 expression is lower in tumors relative to normal tissues. Is this lower expression in human tumors due to mutation or loss of p53? How is SESN2 expression between tumors expressing wild type versus mutant p53? Reanalysis of the various datasets in [Figure 3](#fig3){ref-type="fig"} partitioning tumors based on p53 status would be a significant addition to the paper and overall model. Since the p53 field is heavily debating which of tis transcriptional targets carries tumor suppressive activity, this would be a good contribution to the field.

6\) The experiments on cancer are not compatible with the experiments on colitis as different conditions were used for these experiments. What is the mouse age? Does Sesn2 protects from colitis, ER stress and cell death in the mice treated with 1.5% DSS in the colitis study. It is also not clear how tumor sizes and tumor load were analyzed.

7\) In [Figure 5](#fig5){ref-type="fig"} there is no evidence that Sesn2 expression and mTORC1 activity is somehow affected in tumor samples in control mice. Also the data on 4E-BP1 staining look odd because several differently phosphorylated forms of 4E-BP1 usually appear when cells are stained with 4E-BP1 antibody. Moreover, to analyze mTORC1 activity S6K phosphorylation data should be added to the experiment and several samples should be presented.

8\) [Figure 6](#fig6){ref-type="fig"}: It was recently published by Agarwal et al., Mol. Can. Res 2015 that p53 inactivation in colon cancer cells led to strong suppression of Sesn2 expression as well as expression of some other p53-dependent mTORC1 regulators such as TSC2. Moreover, the control of mTORC1 in HCT116 cells was attributed to regulation of lysosomal dynamic of TSC2 and Rheb but not Sesn2 activity.

9\) The data in [Figure 7A and D](#fig7){ref-type="fig"} are inconsistent. The number and size of colonies look similar between sh-Luc and sh-Sesn2 in [Figure 7A](#fig7){ref-type="fig"} and quite different in [Figure 7D](#fig7){ref-type="fig"}. Moreover, it is not clear how the [Figure 7](#fig7){ref-type="fig"} is relevant to the other parts of the paper. Does 5-Fu and CPT-11 treatments affect mTORC1 activity? Is mTORC1 responsible for the potential effect of Sesn2 on colony formation?

10\) [Figure 7G](#fig7){ref-type="fig"}: Despite the observed phenotypes on colon morphology, it is not clear which mechanisms are responsible for these phenotypes: whether they involve ER stress and mTORC1 regulation or both. To study whether inhibition of inflammation and colon carcinogenesis by Sesn2 is mediated by mTORC1 the authors should verify that the effects observed in Sesn2-null cells can be reversed by treatment with mTORC1 inhibitors.

11\) If Sestrin level were modulated during colitis, the authors should examine the expression levels of Sestrins in DSS-induced colitis model. Are there any changes of Sestrins expression (both mRNA and protein level) before and after DSS treatment in mice?
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Author response

*The reviewers discussed the manuscript and decided to encourage resubmission of a revised manuscript addressing several major concerns: 1) [Figure 1A-C](#fig1){ref-type="fig"}: It is not clear where these samples were obtained from and how they were analyzed. What was used as a control? Although there was a trend for mRNA increase of Sesn2 and Sesn3 in patients (n=10), the error bar is pretty big, which makes the data weak. If the authors really want to make this point, more patients samples are needed.*

The samples in [Figure 1A-C](#fig1){ref-type="fig"} are colon samples from ulcerative colitis patients. The normal tissue is adjacent, non-inflamed tissue. These tissues were histologically confirmed and described previously (Gastroenterology 145:831-41). We have clarified this information and cited proper references in the revised manuscript.

In addition, we realized that the presented data are somewhat misleading because the error bars in [Figure 1A-C](#fig1){ref-type="fig"} of the original manuscript represented standard deviation (SD) in patient samples, which is large in nature. Specifically, SD does not reflect the power of the sample size; therefore, analyzing more patients would not help reduce this error bar. With n=10 per group, which is a reasonable sample size, we were able to detect strong statistical significance in the changes in expression of Sestrin2 and Sestrin3 between control and ulcerative colitis groups (*P*\<0.01 and *P*\<0.05, respectively), and error bars made from the standard error of the mean (SEM) did not overlap between these samples ([Figure 1A-C](#fig1){ref-type="fig"}).

To eliminate the possibility of this potential confusion, we have used SEM error bars, which do reflect the power of the sample size, throughout the manuscript. We also wanted to note that we have eliminated the Crohn's disease group from [Figure 1A-C](#fig1){ref-type="fig"}, because they did not show any statistically significant differences from control group samples.

*2) [Figure 1D](#fig1){ref-type="fig"}: According to the working hypothesis, Sesn2 protects from ER stress and inflammation. Nevertheless, there is no significant difference between 2 mouse strains in body weight during first 7 days of treatment indicating that Sesn2 is not directly involved in control of inflammation and the observed phenotype might be a residual effect of Sesn2 inactivation. The effects of Sesn2 have to be assessed immediately after DSS treatment, and the impact of the DSS treatment on tissue morphology, regulation of Sesn2 protein expression, mTORC1 activity, ER stress levels and the inflammation should be addressed.*

We agree with the reviewers that Sestrin2 may not be directly involved in the control of inflammation. Indeed, our bone marrow transplantation results ([Figure 2](#fig2){ref-type="fig"}) suggest that Sestrin2 in epithelia, rather than in inflammatory cells, is more important for colon homeostasis during DSS insults. Therefore, we performed the reviewer's suggested experiment by examining the colons of WT and *Sesn2*- KO mice right after the 7 days of DSS treatment (DSS -- 7D ONLY; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Consistent with the observation that DSS-induced body weight losses were not significantly different between WT and *Sesn2*-KO mice at this time point ([Figure 1D](#fig1){ref-type="fig"}), there were no detectable changes in colon length ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}), which quantitatively represents tissue damage. Histological degeneration ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), inflammatory gene expression (*TNFα*; [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}) and ER stress target gene expression (*Xbp1s*; [Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}) also did not show any significant difference between the two groups.

According to these new results and the reviewer's suggestion, we have clarified that Sestrin2 is more important in the recovery process, rather than in the initial response to injury, by rewriting text in the Abstract and subtitles.

*3) The mice used in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} are different ages and are not comparable. It is not clear why the authors used 6-month old mice in [Figure 1](#fig1){ref-type="fig"} rather than the younger mice as in [Figure 2](#fig2){ref-type="fig"}. Please clarify.*

As the reviewer indicated, [Figure 1](#fig1){ref-type="fig"} was done with 6-month old mice, while [Figure 2](#fig2){ref-type="fig"} was done with 4-month old mice (1 month after bone marrow transplantation). Both ages are considered to be within the same stage of development/aging, and the mice are age-matched within each experimental set.

The results of [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} should be interpreted in a separate context because the mice in [Figure 2](#fig2){ref-type="fig"} have undergone bone marrow transplantation, which is a severe intervention involving a lethal dose of irradiation. We believe that this procedure made a larger impact than the age difference, and the severe procedure is the reason why the colitis-inducing effect of DSS is different between these two experiments. Still, both of these results solidly support our conclusion that Sestrin2 in the non-hematopoietic compartment is more important for protecting the colon from DSS-induced damage.

In addition, one of our cancer cohorts (n=7) demonstrated that one week of 2.5% DSS treatment killed all two-month-old *Sesn2*-KO mice within the following two weeks, but not WT mice of the same age ([Figure 5A](#fig5){ref-type="fig"}). Therefore, the DSS sensitivity of Sestrin2-deficient mice does not appear to be age-dependent.

*4) In [Figure 2E](#fig2){ref-type="fig"}/F only DSS-treated mice are analyzed. To prove their claim the authors should compare the levels of ER stress in untreated and DSS-treated mice analyzing Sesn2 expression and the expression of the ER markers. Moreover, the protein extracts were not well normalized in [Figure 2E](#fig2){ref-type="fig"} and the actin marker is overexposed. Also the role of Sesn2 and ER stress in regulation of cell death is not addressed directly and not quantitated.*

As the reviewer suggested, we have analyzed the *Sesn2* expression and ER stress signaling in mice during the course of DSS treatment. Consistent with what was formerly reported (Gastroenterology 144:989-1000), DSS treatment induced prolonged ER stress signaling (monitored by expression of *Xbp1s* and other ER stress target genes; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) that was accompanied by modestly increased Sestrin2 expression in the recovery phase ([Figure 2---figure supplement 1C, D](#fig2s1){ref-type="fig"}). Although the actin blot of [Figure 2E](#fig2){ref-type="fig"} was densely exposed, the protein loading was normalized according to the total protein concentration, and non-specific bands in the full image of the same blots (e.g. see CHOP blots in [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}) indicate that the general protein loading was normalized well. In the revised manuscript, we have included additional immunoblot images, in which the actin marker was more lightly exposed ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). In addition, analyses of qRT-PCR data, which was quantitatively normalized by *β-actin* mRNA ([Figure 2F](#fig2){ref-type="fig"}), further confirmed that ER stress is indeed increased in *Sesn2*-KO mice when compared to WT mice. Quantification of colon length ([Figure 1E](#fig1){ref-type="fig"}) unequivocally demonstrated that colons of *Sesn2*-KO mice do not recover from DSS treatment and remain severely damaged. However, it is beyond the scope of our research to determine whether ER stress directly regulates apoptotic cell death or indirectly induces tissue degeneration through disruption of colonic homeostasis.

*5) [Figure 3](#fig3){ref-type="fig"}. The subtle difference in mRNA levels between normal tissue and in tumors can be explained by compositions of different cell types in normal and tumor samples. Surprisingly, there is no significant downregulation of Sesn2 expression during cancer progression. Did the authors carry out an analysis of Sesn2 locus to find if Sesn2 locus has undergone LOH in tumors? Also related to this figure, unlike TP53, which is mutated in about half of all colorectal cancers, SESN2 is rarely mutated. The authors mined several public datasets demonstrating that SESN2 expression is lower in tumors relative to normal tissues. Is this lower expression in human tumors due to mutation or loss of p53? How is SESN2 expression between tumors expressing wild type versus mutant p53? Reanalysis of the various datasets in [Figure 3](#fig3){ref-type="fig"} partitioning tumors based on p53 status would be a significant addition to the paper and overall model. Since the p53 field is heavily debating which of tis transcriptional targets carries tumor suppressive activity, this would be a good contribution to the field.*

We wanted to stress that the Sestrin2 mRNA difference between normal colon and tumors is not subtle, considering that these data are collected from a variety of different human samples. In many different analyses, the magnitude of Sestrin2 suppression in tumors is among the top 1-5% of all suppressed genes ([Figure 5A](#fig5){ref-type="fig"}). The extent of the difference was also exceptionally strong (all studies indicate *P*\<10~-4~ or much lower; in TCGA analysis, *P*=1.6 x 10~-30~). None of the other cell type markers, such as Villin (VIL1, enterocytes), DLL1 (progenitor cells), F4/80 (EMR1, macrophages), Gr-1 (LY6G5B, leukocytes), or β-catenin (CTNNB), showed such strong changes in expression as observed for Sestrin2 ([Figure 3---figure supplement 1A-1E](#fig3s1){ref-type="fig"}). Only some stem cell markers, such as Lgr5, were upregulated (not downregulated) in tumor samples ([Figure 3---figure supplement 1A- 1E](#fig3s1){ref-type="fig"}). These new analyses were included in the revised manuscript.

Regarding the LOH, we did perform a copy number analysis for the *Sesn2* locus; it appeared that copy number of the Sestrin2 locus generally, and significantly, decreases with cancer progression ([Figure 3H](#fig3){ref-type="fig"}). However, the extent of copy number loss was very small (\~10%), suggesting that transcriptional downregulation (which is through p53 loss -- see below), rather than the LOH, is the major mechanism of Sestrin2 loss during colon cancer progression.

It is a very insightful suggestion to analyze the correlation between p53 status and Sestrin2 expression in human colon cancer samples. We were able to perform this analysis using the cancer genome atlas (TCGA) dataset, as it has comprehensive information regarding the genomic status of each tumor, determined by whole genome/exome sequencing. From this database, we were able to classify all the colon tumor samples into the two groups. One group (designated as "p53-mutated") has one or more missense or nonsense coding sequence mutations in the *p53* gene. The other group does not reveal any coding sequence mutations in the *p53* gene; however, it is still possible that these tumors contain *p53* mutations in essential non-coding regions (e.g. promoters, enhancers or introns) or other genomic or epigenetic alterations that can lead to functional p53 inactivation (e.g. MDM2 overexpression). Therefore, this second group was designated as "p53-unknown".

Expressions of *SESN2* and other known p53 target genes were analyzed in three different groups: normal colons, "p53-unknown" tumors and "p53-mutated" tumors.

The analyses gave us very interesting results. First, we found that *SESN2* expression is significantly reduced in "p53-mutated" tumors compared to "p53-unknown" tumors ([Figure 4A](#fig4){ref-type="fig"}), suggesting a role of p53 in controlling *SESN2* expression. This difference was consistently observed in three independent *SESN2* probes ([Figure 4A-C](#fig4){ref-type="fig"}). Strikingly, there were almost no overlaps of *SESN2* expression levels between the normal colon and "p53-mutated" tumor groups ([Figure 4B, C](#fig4){ref-type="fig"}), while *SESN2* levels in "p53-unknown" tumors overlap with both groups ([Figure 4B, C](#fig4){ref-type="fig"}). None of the other known p53 target genes, such as *p21, GADD45A* and *MDM2*, showed this strong correlation: for these genes, considerable overlaps were found between the normal colon and "p53-mutated" tumor groups in individual samples ([Figure 4D-F](#fig4){ref-type="fig"}). Nevertheless, expression levels of these genes have a general positive correlation with expression of *SESN2* in individual samples ([Figure 4D-F](#fig4){ref-type="fig"}), suggesting that *SESN2, p21, GADD45A* and *MDM2* are all regulated through the same p53-dependent mechanism. Indeed, all of these genes are differentially expressed between "p53-unknown" and "p53-mutated" tumor groups ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A-C](#fig4s1){ref-type="fig"}).

Interestingly, some p53 target genes, such as apoptosis mediators *BAX, PUMA* and *p53AIP1* or mTORC1 regulators *TSC2, AMPKβ* and *PTEN*, did not show any differential expression between the "p53-unknown" and "p53-mutated" tumor groups ([Figure 4---figure supplement 1D-J](#fig4s1){ref-type="fig"}), suggesting that the effects of p53 mutations on these genes are minimal in the pathological context of colon carcinogenesis.

These results collectively highlight *SESN2* as a clinically relevant target of p53 during colon carcinogenesis. As the reviewer indicated, there has been a heavy debate in the p53 field about which of its transcription targets is important for its tumor suppressive activity. As we have demonstrated that *SESN2* is one of the most significant p53 targets in colon carcinogenesis, we agree with the reviewer that this is a very important contribution to the field.

*6) The experiments on cancer are not compatible with the experiments on colitis as different conditions were used for these experiments. What is the mouse age? Does Sesn2 protects from colitis, ER stress and cell death in the mice treated with 1.5% DSS in the colitis study. It is also not clear how tumor sizes and tumor load were analyzed.*

As indicated in our original manuscript, the colitis condition (3% or 2.5% DSS) cannot be used for the tumor experiment because it killed the *Sesn2*-KO mice. Also, in the tumor study, we do multiple rounds of DSS treatment and allow the mice to age for an extended period, as it takes time for a tumor to develop. The timeline for both experiments begins with an AOM injection when the mice are 2 months ([Figure 5](#fig5){ref-type="fig"}) or 4 months ([Figure 6](#fig6){ref-type="fig"}, after bone marrow transplantation) of age. After the DSS treatments and tumor incubation periods (as in [Figure 5B](#fig5){ref-type="fig"}), the mice in these studies reach the end of the experiment at around 6 months ([Figure 5](#fig5){ref-type="fig"}) or 8 months ([Figure 6](#fig6){ref-type="fig"}), at which point the analyses were performed. Therefore, regardless of the DSS concentration, the DSS colitis experiment and the AOM/DSS experiment should be considered as separate experiments.

The mechanisms underlying increased susceptibility to colitis and colon cancer may be different from each other. For example, resolution of ER stress and subsequent recovery from DSS insult may be important for the increased colitis phenotype of *Sesn2*-KO mice, while Sestrin2-dependent suppression of mTORC1 and cell growth could be more critical for increased susceptibility of *Sesn2*-KO mice to colon cancer development. In the revised manuscript, we have discussed these possibilities in the Discussion section.

In addition, we have clarified the methods of how we analyzed tumor sizes and tumor load in the cancer studies. A dissecting microscope (4x magnification) was used to assess the tumor number and size. Tumor size was defined as the mean of the two largest diameters measured with digital calipers. Tumor volume was derived from tumor size. Consistent with their histological appearance, a spherical shape was assumed for colon polyps, thus tumor volume = 4/3πr~3~, where r = radius. Tumor burden/load is defined as the total polyp volume per animal, that is the product of polyp number and polyp volume.

*7) In [Figure 5](#fig5){ref-type="fig"} there is no evidence that Sesn2 expression and mTORC1 activity is somehow affected in tumor samples in control mice. Also the data on 4E-BP1 staining look odd because several differently phosphorylated forms of 4E-BP1 usually appear when cells are stained with 4E-BP1 antibody. Moreover, to analyze mTORC1 activity S6K phosphorylation data should be added to the experiment and several samples should be presented.*

As discussed in our former manuscript, mouse AOM/DSS colon tumors do not typically lose p53 (Cancer Res 64: 6394-6401, Cancer Sci 95: 475-480), unlike what is seen in human colon cancers. Therefore, it is expected that Sestrin2 expression and mTORC1 activity are not strongly affected in tumor samples of control mice ([Figure 6G](#fig6){ref-type="fig"}). However, we have demonstrated that p53 loss in mouse colon tumor can also inhibit Sestrin2 expression ([Figure 7C](#fig7){ref-type="fig"}) as observed in human colon cancers ([Figure 4](#fig4){ref-type="fig"}).

The PAGE gel resolution of mouse tissue samples (especially the colon samples) is relatively poor (see the whole blots presented in supplemental figures). For this reason, the phosphorylation-induced 4E-BP1 shifts are not evident from this specific western blot ([Figure 6G](#fig6){ref-type="fig"}). We do see clear 4E-BP1 shifts in cultured cell lysates (see [Figure 7](#fig7){ref-type="fig"}). In the revised manuscript, we have shown additional immunostaining ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}) and immunoblot ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}) results to demonstrate that these changes are reproducible in tissues from different mice. The 4E-BP1 shifts were visible in some of these additional blots, although with a lower resolution when compared to the results from cultured cell lysates.

We agree that S6K is another good readout of mTORC1 activity; however, for an unknown reason, the antibody worked very poorly in these mouse colon samples due to the presence of strong non-specific bands. Still, S6 and 4E-BP1 phosphorylation data (in both immunoblotting and immunostaining) consistently support that mTORC1 is strongly upregulated in Sestrin2-deficient mouse tumors. According to recent studies about mTORC1 signaling in colon (Nature (2015) 517:497-500; J Clin Invest (2013) 123:767-781; PLoS One (2014) 9:e96023), p- S6 and p-4E-BP1 antibodies are reliable reporters of mTORC1 signaling activity in colon tissue. These studies did not include p-S6K analyses.

*8) [Figure 6](#fig6){ref-type="fig"}. It was recently published by Agarwal et al., Mol. Can. Res 2015 that p53 inactivation in colon cancer cells led to strong suppression of Sesn2 expression as well as expression of some other p53-dependent mTORC1 regulators such as TSC2. Moreover, the control of mTORC1 in HCT116 cells was attributed to regulation of lysosomal dynamic of TSC2 and Rheb but not Sesn2 activity.*

We and others have recently shown that Sestrin2 controls lysosomal localization of mTORC1 through modulation of the GATOR complexes (Sci Rep. 2015 5:9502; Cell Rep. 2014 9:1; Cell Rep. 2014 9:1281). In addition to this mechanism, Sestrin2 controls the TSC2-Rheb axis through AMPK activation (Cell 2008 134:451; Science 327:1223). Therefore, the Agarwal et al. findings that p53 affects Rheb signaling do not contradict our conclusion that Sestrin2 controls mTORC1 signaling as a p53 target.

In response to the reviewer's comment, we made a note in the revised manuscript that p53 has other possible targets that can control mTORC1 signaling, such as *TSC2, AMPKβ* and *PTEN* (Cancer Res 67:4043-53). However, these targets were not differentially expressed between "p53-unknown" and "p53-mutated" colon cancer tissues ([Figure 4---figure supplement 1G-J](#fig4s1){ref-type="fig"}), while *SESN2, p21, GADD45* and *MDM2* are all differentially regulated between these groups ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A-C](#fig4s1){ref-type="fig"}). We have included these new analyses in the revised manuscript.

*9) The data in [Figure 7A and D](#fig7){ref-type="fig"} are inconsistent. The number and size of colonies look similar between sh-Luc and sh-Sesn2 in [Figure 7A](#fig7){ref-type="fig"} and quite different in [Figure 7D](#fig7){ref-type="fig"}. Moreover, it is not clear how the [Figure 7](#fig7){ref-type="fig"} is relevant to the other parts of the paper. Does 5-Fu and CPT-11 treatments affect mTORC1 activity? Is mTORC1 responsible for the potential effect of Sesn2 on colony formation?*

In the revised manuscript, we have addressed this issue by repeating both experiments in a single batch, and replacing the old figures ([Figure 7---figure supplement 2A-C](#fig7s2){ref-type="fig"}, in the revised manuscript). The new results are consistent with the former results and clearly show that sh-Sesn2 cells grow faster and are more resistant to 5-FU and CPT-11 treatments.

We have also examined Sestrin2 expression and mTORC1 signaling in RKO cells treated with 5-FU and CPT-11. After the 5-FU or CPT-11 treatments, Sestrin2 expression was slightly elevated in WT cells (sh-Luc; [Figure 7---figure supplement 2D, E](#fig7s2){ref-type="fig"}). Interestingly, mTORC1 signaling, monitored by p-S6K and p-4E-BP1 was prominently upregulated in sh-Sesn2 cells after 5-FU treatment ([Figure 7---figure supplement 2D](#fig7s2){ref-type="fig"}), suggesting that Sestrin2 functions to suppress mTORC1 activation after 5-FU treatment. In contrast, CPT-11 reduced mTORC1 signaling, and Sestrin2 silencing led to persistent mTORC1 upregulation ([Figure 7---figure supplement 2E](#fig7s2){ref-type="fig"}). This mTORC1 upregulation as a result of Sestrin2 loss could have conferred chemoresistance to RKO cells against 5- FU and CPT-11.

Nevertheless, we agree with the reviewers that, although these results are interesting and potentially important in the field of tumor chemoresistance, they are peripheral to the main story. Therefore, we have removed these data from the main figure and moved them into the figure supplement ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}).

*10) [Figure 7G](#fig7){ref-type="fig"}. Despite the observed phenotypes on colon morphology, it is not clear which mechanisms are responsible for these phenotypes: whether they involve ER stress and mTORC1 regulation or both. To study whether inhibition of inflammation and colon carcinogenesis by Sesn2 is mediated by mTORC1 the authors should verify that the effects observed in Sesn2-null cells can be reversed by treatment with mTORC1 inhibitors.*

We have shown that increased colony growth phenotypes of either Sestrin2-silenced or p53-mutated (SW480; therefore Sestrin2-downregulated) cells can be suppressed by treatment with rapamycin, an mTORC1 inhibitor ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Therefore, the role of Sestrin2 in inhibiting colon tumor growth seems to be mainly dependent on mTORC1 suppression.

11\) If Sestrin level were modulated during colitis, the authors should examine the expression levels of Sestrins in DSS-induced colitis model. Are there any changes of Sestrins expression (both mRNA and protein level) before and after DSS treatment in mice?

We have shown that Sestrin2 level, in both mRNA and protein levels, was moderately increased after DSS treatment ([Figure 2---figure supplement 1C, D](#fig2s1){ref-type="fig"}). This observation is consistent with the findings from the human colitis samples ([Figure 1A-C](#fig1){ref-type="fig"}).

[^1]: These authors contributed equally to this work.
